Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.

<< Back to News

07/19/17 AO -- Zarxio Outpatient Use update

From: Amanda Ouzts
To: Pharmacists
Sent: Wednesday, July 19, 2017 10:44:07 AM
Subject: Zarxio

All,

I just wanted to let everyone know that by the end of the day today we will have replaced Neupogen in all of the outpatient medical Pyxis machines with Zarxio. Zarxio is a biosimilar to Neupogen and will now be the outpatient G-CSF workhorse. Granix will still be the inpatient G-CSF workhorse, and should still be used for all inpatient areas.

If you receive an order for Neupogen in one of the outpatient areas, please do not verify it as is. Zarxio is built in iCare and should be entered dose for dose instead of Neupogen. We will be working to get the Neupogen outpatient pathway to automatically interchange to Zarxio.

This new interchange does not apply to St. Jude outpatients, only adult outpatient areas.

Please let me know if you have any questions.

Thank you,

Amanda Ouzts, Pharm.D., BCPS
Clinical Pharmacy Specialist, Oncology  






This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.

Copyright © 2024 Rpharmy, LLC ­ All Rights Reserved